MapLight Therapeutics Inc MPLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $9.63
- Day Range
- $9.43–10.17
- 52-Week Range
- $9.10–40.43
- Bid/Ask
- $9.50 / $10.10
- Shares Outstanding
- 55.58M
- Market Cap
- $545.75M
- Volume/Avg
- 565,742 / 853,964
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 133
- Website
- https://www.maplightrx.com
Valuation
|
Metric
|
MPLT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.28 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MPLT
|
|---|---|
Quick Ratio | 15.79 |
Current Ratio | 16.52 |
Interest Coverage | — |
Quick Ratio
MPLT
Profitability
|
Metric
|
MPLT
|
|---|---|
Return on Assets (Normalized) | −54.70% |
Return on Equity (Normalized) | −127.98% |
Return on Invested Capital (Normalized) | −60.40% |
Return on Assets
MPLT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$^s?Z! | LOCK|DX#X | $128B | |||
| Moderna Inc
MRNA
| LOCK|D#nmjCD | LOCK|VvS | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|n<VXXc | LOCK|!Ch@ | $76B | |||
| argenx SE ADR
ARGX
| LOCK|%Md<z^ | LOCK|pT | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!H$#>X! | LOCK|j?@ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<pll<g^ | LOCK|Bz^D | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|KbnV$LCf | LOCK|>b?C | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|$&$MxDN | LOCK|n$ | $24B | |||
| Incyte Corp
INCY
| LOCK|!P&^^@@ | LOCK|^^S | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|yl!@Cc | LOCK|@d | $15B |
United States